



ESSEX BIO-TECHNOLOGY LIMITED
億勝 生物 科技 有 限 公 司

(Stock Code: 1061)

Essex Bio-Technology appoints Dr. Xue Qi as Chief Scientific Officer for its R&D Centre in USA



Hong Kong, 9 April 2018 — — ESSEX BIO-TECHNOLOGY LIMITED (“EssexBio” or the “Group”—Stock code: 1061) is pleased to announce its appointment of Dr. Xue Qi (MD, PhD.) as Chief Scientific Officer of EssexBio and Vice President (Science of Technology) of Essex Bio-Investment Limited. Dr. Xue Qi will lead the R&D Centre in USA, which is being set-up, for R&D projects, primarily in oncology, ophthalmology & dermatology.

Dr. Xue is a well-known global medical science expert in anticancer drug discovery and development. He is highly experienced in tumor microenvironment, immune-oncology and angiogenesis assessment. In June 2014, Dr. Xue obtained his Clinical Research Scholar Certificate from Harvard Medical School in the USA. Dr. Xue graduated from Gunma University in Japan with a PhD degree in Pathology in 2001.

Prior to joining the Group, Dr. Xue has worked for Eli Lilly as one of the key members in its R&D team. He also served as a postdoctoral fellow in Harvard Medical School for nearly seven years since 2002.

The Board of Directors of EssexBio is confident that the addition of Dr. Xue Qi as its CSO will strengthen the Group’s ability in drug discovery and broaden the capability of translational and therapeutics research in its current R&D centre in the PRC.

-END-

About EssexBio

Essex Bio-Technology Limited is a bio-pharmaceutical company, started in early 90's, a pioneer in bio-pharmaceutical industry in China, that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF, a basic fibroblast growth factor, with established mechanism of action in cellular proliferation, differentiation and migration.

The Company currently has five commercialised bio-pharmaceutical products, formulated with rb-bFGF, in China, out of which 3 are approved by CFDA as Category I drugs. The products are being marketed & sold as Beifushu, Beifuji & Beifuxin, for treatment of ocular surface wounds and topical (skin) surface wounds respectively. Beifuji is the first in the world to have obtained approval from CFDA for commercialisation in 1998.

The Company focuses on two main therapeutics; Ophthalmology and Surgical arena of topical (skin) surface wounds, which primarily covers Dermatology, Stomatology and Obstetrics & Gynaecology, while selectively pursuing therapeutics in Neurology, Oncology and Orthopaedics. The Company maintains a pipeline of multi-project in R&D and on various stages of clinical programs, of which several projects involving growth factors and antibody and a handful of projects are on unit dose for Ophthalmic and Respiratory disease.

The Company's products and its 3rd party products are marketed and sold through more than 5,400 hospitals in China and are managed directly by its 39 regional sales offices with about 1,410 sales and marketing people. Its 3rd party products; notably are inclusive of Xalacom eye drops and Xalatan eye drops of Pfizer (for Ophthalmology), Iodized Lecithin Capsules (for Ophthalmology), Yi Xue An Granules (for Obstetrics & Gynaecology) and Carisolv Products (for Stomatology).

This press release is issued by Zhixin Investor Relations Consultant Limited on behalf of **Essex Bio-Technology Limited**.

For further information, please contact:
Zhixin Investor Relations Consultant Limited
Ms. Tan Ronghua
Tel: 0755 8323 9767
E-mail: tanronghua@zhixincaijing.com